Resultados de la búsqueda 241-250 of 12089 for LDL
placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...
Recently, a new medication called Tolvaptan has been approved by the FDA to slow progression of ADPKD. Accurate, MR based kidney volume measurements are the ...
After enrollment, patients will receive one cycle of Induction chemotherapy. Subsequent therapy will be based upon MIBG avidity and ALK status. Patients with ...
The natural course of autosomal dominant polycystic kidney disease (ADPKD) is highly variable and typically characterized by progressive enlargement of ...
Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to analyze the effect of parity, menopause and reproductive lifespan on kidney ...
Jacksonville, Fla. The primary objective of the study is to compare outcomes of patients undergoing sarcoma reconstructive surgery using fluorescence ...
The second objective of this pilot research protocol is to compare the image quality from MRI images acquired on the SIGNA PET/MR to clinical MR images acquired ...
Rochester, Minn. The purpose of this study is evaluate the outcomes and complications in patients who underwent a rotator cuff repair. Benevolent Tumor Tissue ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
Rochester, Minn. This is a study to generate feasibilty data regarding the collection of health and psychosocial outcomes after acquired spinal cord injury (SCI) ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?